Ekso Bionics climbs on FDA nod for use of robotic exoskeleton on MS patients

Chronoscale

13/06/2022 15:43

** Shares of medical device maker Ekso Bionics  EKSO.O  jump
20% to $2.18, set for their best day since Feb. 8
    ** Gains come in sharp contrast to the broader markets,
which are being weighed by mounting fears over an aggressive
U.S. interest rate hike this week  .N 
    ** Co gets the clearance of U.S. Food and Drug
Administration to market its robotic exoskeleton device for use
on multiple sclerosis (MS) patients
    ** MS is a chronic disease affecting the central nervous
system (the brain and spinal cord)
    ** EksoNR is a robotic exoskeleton that was previously
cleared by the FDA for stroke and spinal cord injury
rehabilitation in 2016 and acquired brain injury in 2020
    ** Stock down about 20% YTD

 (Reporting by Medha Singh)
 ((medha.singh@thomsonreuters.com))